舒利迭吸入对稳定期COPD患者的疗效观察  

The study of seretide on lung function in patients with COPD

作　　者：刘雪梅[1] 张作清[1] 张昌红[1] 魏萍[1] 

机构地区：[1]北京市石景山医院,100043

出　　处：《中国医学创新》2010年第23期15-16,共2页Medical Innovation of China

摘　　要：目的研究舒利迭(沙美特罗/替卡松粉吸入剂,50μg/250μg)对稳定期慢性阻塞性肺病(COPD)患者肺功能的影响。方法将明确诊断的60例COPD患者随机分为对照组和试验组,对照组给予抗感染、解痉平喘、祛痰等基础治疗;试验组在此基础上给予舒利迭50μg/250μg剂型,1吸/次,2次/d,疗程为3个月。测定肺功能指标FEV1、FEV1/预计值的百分率,评价治疗前后肺功能的变化、血气分析结果及临床症状积分情况。结果在试验组FEV1、FEV1/预计值的百分比较试验前均有显著提高(P<0.01),对照组FEV1和FEV1/预计值的百分比与试验前的差异无显著性(P>0.05);两组患者治疗后,PaO_2均升高(P<0.05),PaCO_2(P<0.05)均下降,两组治疗前后PaO_2及PaCO_2差值,均以试验组高于对照组(P<0.05);临床症状积分改善明显。结论舒利迭吸入剂治疗稳定期患者能够明显改善患者肺功能,有一定的临床应用价值。Objective To evaluate the effect of Seretide （salmeterol 50 μg and flutieasone propionate 250 μg）on lung function in patients with chronic obstructive pulmonary disease （COPD） on stable stage. Methods 60 patients who were diagnozed as COPD were divided into groups：the control group was given basic treatment such as antimicrobid therapy, spasmolysis, antiastbma, expelling phlegm, and test group whose patients were given seretide 50 μg/250 μg per inhale twice every day for 3 monthes besides the control group, streatment, then the percentage of pulmonary functional paramenters including FEVI, FEV1 or FVC and FEV1 in the anticipation value were examined and then the pulmonary functional changes, blood gas analysis and clinical symptom integral before and after therapy were evaluated. Results In the experimental group, FEV1, FEV1/predictive value were all increased, compared to those before treatment （ P 〈 0. 01 ）, in the control group, FEV1, FEV1/ predictive value were almost the same, compared to those before treatment （ P 〉 0.05 ） ; the level of PaO2 of both groups increased ,while the level of PaCO2 decreased. The value changes of two parameters of treatment group were higher than those of the control group, integral calculus of clinical symptom surpassed control group. Conclusion Treatment with seretide in COPD can improve lung function in COPD patients in stable stage. It has certain value on clinical application.

关 键 词：阻塞性肺疾病 舒利迭 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]